Mandate

Vinge advises BioGaia and its subsidiary Infant Bacterial Therapeutics in connection with a share distribution and separate listing

February 15, 2016

Vinge advises BioGaia AB (publ) and its subsidiary Infant Bacterial Therapeutics AB (publ) ("IBT") in connection with the proposed distribution of BioGaia’s shares in IBT to the shareholders of BioGaia. In connection with the distribution, IBT will apply for listing of the company's series B shares on Nasdaq First North. IBT is developing a drug (IBP-9414) against necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Vinge's team consists of Erik Sjöman, Dain Hård Nevonen, Ludvig Frithiof and Joel Wahlberg. Tora Hansjons advises on tax matters.

Vinge’s experts provide an insight into Swedish maritime law in the latest edition of International Comparative Legal Guide – Shipping Law 2022

Vinge’s experts in martime and transport law have again contributed to the Swedish chapter on maritime law in the International Comparative Legal Guides (ICLG).
August 10, 2022

Sanctions update 22 July

Further to our previous sanctions updates of 25 February, 3 March, 11 March, 16 March , 14 April and June 8, we herewith provide a further update of recent sanctions developments following Russia’s war against Ukraine:
July 26, 2022

A new EU instrument for international procurement (IPI)

On 17 June 2022, the Council adopted a regulation on a new instrument for international procurement (“IPI”), following the formal adoption of the IPI at the European Parliament plenary session on 9 June 2022. The general objective of the IPI is to create reciprocity in the access to international public procurement markets by enabling the Commission to undertake investigations and adopt measures to open and improve access to third-country public procurement and concession markets.
July 11, 2022